Innovation1 Biotech Inc. (IVBT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Innovation1 Biotech Inc. (IVBT) trades at $0.00 with AI Score 47/100 (Grade C). Innovation1 Biotech Inc. is a biotechnology company focused on drug discovery, particularly in developing modified botanical Schedule 1 molecules. Market cap: $4,494, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for IVBT: IVBT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IVBT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IVBT: the 1 perspectives are evenly split.
How is this calculated? →Innovation1 Biotech Inc. (IVBT) Healthcare & Pipeline Overview
Innovation1 Biotech Inc. specializes in drug discovery with a focus on synthetic prodrugs derived from botanical sources, addressing unmet medical needs in mental health and pediatric conditions.
What Is the Investment Thesis for IVBT?
Innovation1 Biotech Inc. is positioned for growth through its innovative pipeline of synthetic prodrugs targeting significant medical conditions. The company’s focus on psychedelic compounds and cannabinoids aligns with emerging trends in mental health treatment and chronic conditions, potentially offering substantial market opportunities. As the firm progresses its five prodrugs through preclinical development, successful advancements could lead to partnerships or funding opportunities that enhance its financial stability. The current lack of competition in its specific therapeutic areas, such as pediatric epilepsy and addiction treatment, further strengthens its market position. However, the company faces risks associated with regulatory hurdles and the inherent uncertainties of drug development timelines, which could impact its ability to bring products to market within anticipated timeframes.
Based on FMP financials and quantitative analysis
IVBT Key Highlights
- Market Cap: $0.00B, indicating a nascent stage in its market presence.
- Beta: 5.83, reflecting high volatility compared to the market.
- Dividend Yield: None, as the company does not currently distribute dividends.
- Pipeline includes five proprietary prodrugs in preclinical development, targeting unique medical conditions.
- Established in 2014, with a rebranding to Innovation1 Biotech Inc. in March 2022.
Who Are IVBT's Competitors?
IVBT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CMPS COMPASS Pathways plc | $12.94 | -5.03% | $1.24B | 48 |
| AXSM Axsome Therapeutics, Inc. | $240.85 | -1.42% | $12.39B | 31 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IVBT's Key Strengths?
- Innovative pipeline of synthetic prodrugs addressing significant medical needs.
- Established expertise in drug discovery and development.
- Strong focus on mental health and pediatric conditions, which are gaining attention.
What Are IVBT's Weaknesses?
- Limited resources with only one employee, impacting operational capacity.
- High volatility and risk associated with early-stage biotechnology companies.
- Lack of established revenue streams due to preclinical status.
What Could Drive IVBT Stock Higher?
- Progress in preclinical development of proprietary prodrugs, which could lead to partnerships or funding.
- Research into the efficacy of psychedelic compounds for mental health treatment.
- Potential regulatory approvals for clinical trials targeting pediatric epilepsy and addiction.
- Development of partnerships with research institutions for collaborative studies.
- Increased public awareness and acceptance of psychedelic therapies, which may enhance market opportunities.
What Are the Key Risks for IVBT?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory challenges that could delay drug development timelines.
- High volatility in the biotechnology sector impacting investor sentiment.
- Competition from larger, established pharmaceutical companies with more resources.
- Uncertainties surrounding the efficacy and safety of new drug formulations.
- Market risks related to the acceptance of psychedelic therapies.
What Are the Growth Opportunities for IVBT?
- Growth opportunity 1: The increasing acceptance of psychedelic therapies for mental health conditions presents a significant market opportunity for Innovation1 Biotech. The global market for psychedelic drugs is projected to reach $6.85 billion by 2027, expanding at a CAGR of 16.3%. This growth is driven by rising awareness and research supporting the efficacy of these treatments, particularly for PTSD and depression, which aligns with Innovation1 Biotech's product pipeline.
- Growth opportunity 2: The pediatric epilepsy market is witnessing a surge in demand for innovative treatments, with an estimated market size of $3.5 billion by 2025. Innovation1 Biotech's focus on cannabinoid prodrugs targeting refractory pediatric epilepsy positions it to capture a share of this growing market, especially as traditional treatments often fall short in efficacy.
- Growth opportunity 3: The cannabis-derived pharmaceutical market is expected to grow significantly, with projections estimating a market value of $56.7 billion by 2025. Innovation1 Biotech’s development of cannabinoid prodrugs targeting conditions such as hypertrophic scarring and inflammation of the eye could tap into this expanding market, leveraging the increasing legalization and acceptance of cannabis-based therapies.
- Growth opportunity 4: As the healthcare industry increasingly prioritizes personalized medicine, Innovation1 Biotech's focus on synthetic prodrugs allows for tailored therapeutic solutions that meet individual patient needs. This trend is expected to drive demand for innovative drug formulations, providing a competitive edge as the market shifts towards more customized treatment approaches.
- Growth opportunity 5: The company’s ongoing research into addiction therapies aligns with a growing public health focus on substance abuse treatment. The addiction treatment market is projected to reach $35 billion by 2027, providing a robust opportunity for Innovation1 Biotech to introduce its innovative cannabinoid and tree bark-sourced psychedelic therapies.
What Opportunities Does IVBT Have?
- Growing acceptance and legalization of psychedelic therapies.
- Expanding market for cannabinoid-based treatments.
- Potential partnerships with larger pharmaceutical companies for development.
What Threats Does IVBT Face?
- Regulatory hurdles in drug development and approval processes.
- Intense competition from both established and emerging biotech firms.
- Market risks associated with the volatility of the biotechnology sector.
What Are IVBT's Competitive Advantages?
- Unique focus on synthetic prodrugs derived from botanical sources.
- Specialization in under-researched therapeutic areas such as pediatric epilepsy and addiction.
- Strong potential for intellectual property protection through proprietary formulations.
- Ability to leverage emerging trends in mental health and cannabinoid therapies.
- Small, agile team allows for rapid decision-making and innovation.
What Does IVBT Do?
Founded in 2014, Innovation1 Biotech Inc., originally known as Gridiron BioNutrients, Inc., has established itself as a pioneering drug discovery enterprise based in Somerville, US. The company is dedicated to developing modified botanical Schedule 1 molecules, leveraging innovative approaches to create synthetic prodrugs aimed at treating a range of medical conditions. Currently, Innovation1 Biotech's pipeline includes five proprietary prodrugs in preclinical development, each targeting specific health issues. Among these, a notable psychedelic compound derived from mushrooms is designed to address post-traumatic stress disorder and depression, while another cannabinoid and tree bark-derived psychedelic aims to combat addiction. Additionally, the company is developing three cannabinoid prodrugs targeting refractory pediatric epilepsy, hypertrophic scarring, and inflammation of the eye. The firm’s commitment to addressing significant healthcare challenges positions it uniquely within the biotechnology sector, focusing on novel therapeutic solutions that are currently underrepresented in the market. With a small team of one employee, led by CEO Francis Knuettel, Innovation1 Biotech is poised to make strides in the healthcare landscape, particularly as it navigates the complexities of drug development and regulatory approval processes.
What Products and Services Does IVBT Offer?
- Develops modified botanical Schedule 1 molecules for medical use.
- Focuses on creating synthetic prodrugs targeting various medical conditions.
- Currently has five proprietary prodrugs in preclinical development.
- Targets mental health issues such as PTSD and depression.
- Aims to address pediatric epilepsy and other chronic conditions.
- Operates primarily within the United States healthcare market.
How Does IVBT Make Money?
- Revenue generation through the successful development and commercialization of proprietary prodrugs.
- Potential partnerships and collaborations with larger pharmaceutical firms for product development.
- Grants and funding opportunities aimed at supporting innovative drug research.
- Intellectual property licensing for proprietary drug formulations.
- Future revenue from sales of approved medications targeting unmet medical needs.
What Industry Does IVBT Operate In?
The biotechnology industry is characterized by rapid innovation and significant investment, particularly in drug development targeting unmet medical needs. The global biotechnology market is projected to grow at a CAGR of approximately 7.4% from 2021 to 2028, driven by advancements in genetic research, personalized medicine, and the increasing prevalence of chronic diseases. Innovation1 Biotech Inc. is strategically positioned within this landscape, focusing on synthetic prodrugs that leverage botanical sources, an area that is gaining traction as regulatory frameworks evolve to accommodate novel therapeutic approaches. The competitive landscape includes a mix of established players and emerging firms, with Innovation1 Biotech's unique focus on psychedelic and cannabinoid therapies setting it apart.
Who Are IVBT's Key Customers?
- Healthcare providers seeking innovative treatment options.
- Patients suffering from mental health issues and chronic conditions.
- Pharmaceutical companies interested in partnerships for drug development.
- Research institutions focused on drug discovery and development.
- Investors looking to support biotechnology innovations.
How Innovation1 Biotech Inc. Is Valued
Innovation1 Biotech Inc. carries a market capitalization of 4K, placing it in the micro-cap category. Relative to its peer group, IVBT's quantitative score of 47/100 is below the peer average of 63/100.
Company Profile
Innovation1 Biotech Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Somerville, US. The company is led by CEO Francis Knuettel. IVBT has traded publicly since 2017.
F-Score 2/9Financial Health
Innovation1 Biotech Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
IVBT Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that executives believe in the potential for growth.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approach and potential market expansion.
- Analysts have noted a strong pipeline of upcoming products that could enhance revenue and market share.
- Social media buzz has increased, with many users expressing optimism about the company's strategic partnerships and collaborations.
Bear Case
- Concerns over recent earnings reports have led to skepticism regarding the company's ability to sustain growth in the near term.
- Negative sentiment has emerged from discussions about competition in the market, which could impact IVBT's market position.
- Some community members express doubt about the effectiveness of the company's recent initiatives, fearing they may not yield the expected results.
- Recent regulatory challenges have raised red flags, leading to increased scrutiny and concern about potential operational hurdles.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
IVBT Latest News
No recent news available for IVBT.
IVBT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IVBT.
Price Targets
Wall Street price target analysis for IVBT.
IVBT MoonshotScore
What does this score mean?
The MoonshotScore rates IVBT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Francis Knuettel
CEO
Francis Knuettel has been at the helm of Innovation1 Biotech Inc. since its inception in 2014. With a background in biotechnology and a passion for innovative healthcare solutions, he has guided the company through its early stages of development. His experience includes roles in research and development within the biotech sector, where he has cultivated a deep understanding of drug discovery processes and regulatory landscapes.
Track Record: Under Francis Knuettel's leadership, Innovation1 Biotech has transitioned from Gridiron BioNutrients, Inc. to its current focus on synthetic prodrugs. His strategic vision has positioned the company to explore novel therapeutic avenues, particularly in the fields of mental health and pediatric medicine.
IVBT OTC Market Information
The OTC Other tier includes companies that do not meet the financial or regulatory requirements for listing on major exchanges like NYSE or NASDAQ. This tier often features smaller, less liquid stocks, which can lead to higher volatility and trading costs compared to more established companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited operational history and financial data due to its small size.
- Higher volatility associated with OTC stocks compared to those on major exchanges.
- Potential lack of investor interest leading to liquidity issues.
- Verify the company's financial health and funding status.
- Assess the progress of drug development and clinical trials.
- Confirm the legitimacy of the management team and their experience.
- Review any regulatory filings or disclosures made by the company.
- Investigate potential partnerships or collaborations in the pipeline.
- Established in 2014, indicating some operational history.
- Focus on innovative drug development in a growing market.
- Leadership with experience in biotechnology and drug discovery.
Innovation1 Biotech Inc. Healthcare Stock: Key Questions Answered
What does Innovation1 Biotech Inc. do?
Innovation1 Biotech Inc. is a biotechnology company focused on drug discovery, particularly developing modified botanical Schedule 1 molecules. The company is engaged in creating synthetic prodrugs aimed at treating a variety of medical conditions, including mental health issues such as PTSD and depression, as well as pediatric epilepsy and addiction.
What is Innovation1 Biotech Inc.'s drug pipeline status?
Innovation1 Biotech Inc. currently has five proprietary prodrugs in preclinical development, each targeting specific medical conditions. These include a psychedelic compound derived from mushrooms for PTSD and depression, a cannabinoid for addiction, and three additional cannabinoid prodrugs aimed at pediatric epilepsy, hypertrophic scarring, and inflammation of the eye.
What are the main risks for IVBT?
Innovation1 Biotech Inc. faces several risks, including regulatory hurdles that could impact the timelines for drug development and approval. The company operates in a highly volatile biotechnology sector, where investor sentiment can fluctuate significantly. Additionally, competition from larger pharmaceutical companies and uncertainties surrounding the safety and efficacy of new drug formulations present ongoing challenges.
What are the key factors to evaluate for IVBT?
Innovation1 Biotech Inc. (IVBT) holds an AI score of 47/100 (low). Not financial advice.
How frequently does IVBT data refresh on this page?
IVBT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IVBT's recent stock price performance?
Innovation1 Biotech Inc. (IVBT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline of synthetic prodrugs addressing significant medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IVBT overvalued or undervalued right now?
Valuing Innovation1 Biotech Inc. (IVBT) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying IVBT?
Before investing in Innovation1 Biotech Inc. (IVBT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Company operates in a high-risk sector with limited resources and operational history.